Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Binghao ZhaoYiping Wei

Abstract

A role for erlotinib and bevacizumab as single agents has been established in the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of erlotinib in combination with bevacizumab compared with single agents remain unclear. This meta-analysis aimed to investigate the status of this combined strategy in NSCLC. We systematically searched relevant databases for randomized controlled trials (RCTs) on the use of erlotinib plus bevacizumab in NSCLC. The main outcomes analysis reported overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse effects. Random-effects models were used to estimate pooled hazard ratio and relative risk. Ten studies with a total of 2802 participants were eligible for meta-analysis, the results of which suggested erlotinib with bevacizumab failed to significantly enhance either OS (95% CI: 0.87-1.12; P = 0.825) or ORR (95% CI: 0.69-1.67; P = 0.758). Though PFS was modestly improved, there was no statistical significance (5.55 months vs. 4.67 months, 95% CI: 0.63-1.15; P = 0.297). Incidence of rash or diarrhea was higher in the combination group than in the single-agent group. Subgroup analysis showed encouraging OS (95% CI: 0.29-0.69; P <...Continue Reading

References

Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jul 15, 2005·The New England Journal of Medicine·Ming-Sound TsaoFrances A Shepherd
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
May 24, 2007·British Journal of Cancer·T Kamba, D M McDonald
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Apr 19, 2012·JAMA : the Journal of the American Medical Association·Junya ZhuDeborah Schrag
Sep 27, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Francesco ZappaUNKNOWN Swiss Group for Clinical Cancer Research (SAKK)
Nov 13, 2012·Anti-cancer Agents in Medicinal Chemistry·Antonio PassaroEnrico Cortesi
Jan 1, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Wallace AkerleyChakravarthy Reddy
Aug 1, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Aug 15, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fairooz KabbinavarBruce E Johnson
Mar 21, 2015·The European Respiratory Journal·Michael ThomasUNKNOWN ABC-Lung Cancer Group
Apr 29, 2015·JAMA : the Journal of the American Medical Association·Lesley A StewartUNKNOWN PRISMA-IPD Development Group
May 13, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew J NiederstJeffrey A Engelman
Sep 10, 2015·Cancer Chemotherapy and Pharmacology·Kyoko OtsukaNobuyuki Katakami
Sep 16, 2015·International Journal of Cancer. Journal International Du Cancer·Koh FurugakiNaoki Harada
Nov 6, 2015·International Journal of Cancer. Journal International Du Cancer·Joan MinguetPeter Bramlage
Mar 8, 2016·Expert Opinion on Biological Therapy·Tania LosannoCesare Gridelli
Mar 10, 2016·International Journal of Cancer. Journal International Du Cancer·Kirstin PirieUNKNOWN Million Women Study Collaborators
Jun 25, 2016·Therapeutic Advances in Respiratory Disease·Laurent GreillierFabrice Barlesi

❮ Previous
Next ❯

Citations

Aug 15, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vanita NoronhaKumar Prabhash
Jul 8, 2020·Journal of Cancer Research and Clinical Oncology·Thierry LandreChristos Chouaid
Nov 25, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ching-Yao YangChong-Jen Yu
Oct 29, 2020·Archives of Toxicology·Jukka HakkolaOlavi Pelkonen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.